Laval, Quebec-based Valeant has been trying to rebuild its business and regain investor confidence after the company came under investigations over its accounting and pricing practices. The company said it now expects 2017 adjusted earnings before interest, tax, depreciation and amortization (EBITDA) of $3.60-$3.75 billion, up from its previous forecast of $3.55-$3.70 billion. Valeant has been focusing on its dermatology, eyecare and gastrointestinal units while selling off some other assets as it looks to pay down its heavy debt, racked up after years of acquisitions. The troubled drugmaker said it had lowered its debt by $1.3 billion in the latest quarter, and that its long-term debt was $28.54 billion as of March 31. Valeant is on pace to meet its target of repaying $5 billion in debt between August 2016 and February 2018, Chief Executive Joe Papa told shareholders last week.